Ligand Pharmaceuticals (LGND) Net Cash Flow (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Net Cash Flow of -$59.8 million for Q1 2026, down 265.43% sequentially from $36.1 million in Q4 2025, and down 136.34% YoY from $164.5 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Net Cash Flow (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Net Cash Flow for 17 years, with the latest figure at -$59.8 million in Q1 2026.
- Quarterly Net Cash Flow fell 136.34% year-over-year to -$59.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.8 million (up 3538.0% YoY) and the FY2025 annual result came in at $100.3 million, up 98.44% from the prior year.
- Net Cash Flow fell to -$59.8 million in Q1 2026 per LGND's latest filing, from $36.1 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $69.3 million in Q3 2025 and troughed at -$60.3 million in Q2 2023.
- A 5-year average of $5.6 million and a median of $3.1 million in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Net Cash Flow surged 1146.58% in 2022, then tumbled 637.71% in 2023.
- Over 5 years, Net Cash Flow stood at $40.9 million in 2022, then sank by 92.43% to $3.1 million in 2023, then jumped by 230.62% to $10.2 million in 2024, then jumped by 253.08% to $36.1 million in 2025, then slumped by 265.43% to -$59.8 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$59.8 million, $36.1 million, and $69.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 891.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 891.57 Mn |
| Jun 30, 2026 | 891.57 Mn |
| Mar 31, 2026 | -59.79 Mn |
| Mar 31, 2026 | -59.79 Mn |
| Dec 31, 2025 | 36.14 Mn |
| Dec 31, 2025 | 36.14 Mn |
| Sep 30, 2025 | 69.29 Mn |
| Sep 30, 2025 | 69.29 Mn |
| Jun 30, 2025 | 20.13 Mn |
| Jun 30, 2025 | 20.13 Mn |
| Mar 31, 2025 | -25.30 Mn |
| Mar 31, 2025 | -25.30 Mn |
| Dec 31, 2024 | 10.24 Mn |
| Dec 31, 2024 | 10.24 Mn |
| Sep 30, 2024 | 45.10 Mn |
| Sep 30, 2024 | 45.10 Mn |
| Jun 30, 2024 | -31.95 Mn |
| Jun 30, 2024 | -31.95 Mn |
| Mar 31, 2024 | 27.14 Mn |
| Mar 31, 2024 | 27.14 Mn |